FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
- Per protocol mpMRI before biopsy at one year, and then at X years?
- For cause only MRI during follow-up, if PSA kinetics are suspicious?
- Followed by targeted biopsies if mpMRI shows a lesion with a PIRADS score of above 3?
- Is mpMRI sufficient to detect disease progression?
According to the most recent EAU guidelines, mpMRI should not solely replace repeat biopsy during AS. Moreover, the use of mpMRI prior to any follow-up biopsy is not supported by any strong evidence. Robust data on the use of repeat mpMRI instead of repeat biopsy in AS is currently lacking.3 However, in patients considered for AS, using mpMRI and targeted biopsies at entry is associated with a progression rate of 14-16% at 2 years.4
In conclusion, low-risk men with negative mpMRI may have indeed favorable outcome on AS, regardless of the extent of low-grade cancer at biopsy. The follow-up strategy still relies mainly on clinical and biopsy assessment. It is based on serial digital rectal examinations (at least once a year), PSA (at least once every 6 months), and repeated biopsy (at a minimum interval of 3-5 years). MPMRI cannot be used as a stand-alone tool to trigger follow-up biopsies.3
1. Nasin, J Urol 2017
2. Watson-Diaz, J Urol 2015
3. Briganti A. EAU position on active surveillance. Eur Urol 2018
4. Thurtle. BJU Int. 2018
Presented by: Arnauld Villers, MD, Lille University, France
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 FOIU 4th Friends of Israel Urological Symposium, July 3-5. 2018, Tel-Aviv, Israel
Read the Opposing Argument: Can MRI Replace Biopsy in Men on Active Surveillance? - NO